COSCIENS Partners for Strategic Distribution of Macrilen®
TORONTO, ONTARIO, Dec. 01, 2025 — COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF), a company dedicated to advancing life sciences through innovative therapeutic solutions, has made a significant stride in its growth strategy. The company has secured an exclusive distribution agreement with Wuzhou Drug International Trading Limited to deliver Macrilen® (macimorelin) across key regions, including Singapore and the Greater Bay Area.
Details of the Distribution Agreement
In this strategically valuable agreement, Wuzhou takes on the responsibility for the administrative and operational processes required to bring Macrilen® to market. This includes crucial tasks such as registration, importation, and eventual commercialization, aimed squarely at consumers in Hong Kong, Macao, Guangdong, and Hainan. With a commitment of around €800,000 for initial orders, this partnership fortifies COSCIENS’ position in these high-potential markets.
Expedited Market Access
The distribution strategy leveraged under the “Hong Kong and Macao Medicine and Equipment Connect” policy is set to facilitate faster access to the healthcare markets. By capitalizing on this initiative, COSCIENS aims to ensure that patients experience minimal delays in access to essential diagnostic solutions for Adult Growth Hormone Deficiency (AGHD).
Management Insight and Future Goals
Dr. Matthias Gerlach, Senior Vice-President and Managing Director at Aeterna Zentaris GmbH, expressed enthusiasm about this collaboration, praising Wuzhou's regulatory expertise and strong market presence. He emphasized this agreement as not just a business transaction but a key strategy in realizing the full potential of their lead product, Macrilen®. Dr. Gerlach noted that this partnership provides a unique opportunity to fulfill an unmet need for convenient diagnostic options, which is critical for patients suspected of having growth hormone deficiency.
Enhancing Patient Outcomes
The collaboration is framed within the critical context of improving health outcomes. By facilitating earlier and more accurate diagnoses of AGHD, COSCIENS is positioning itself not just as a pharmaceutical provider, but as a partner in advancing patient health across Asia.
Wuzhou’s Commitment to Innovation
Wuzhou Drug International, headquartered in Macao, stands poised to play a pivotal role in this distribution chain. The company specializes in bringing innovative healthcare solutions to market, focusing on areas like ophthalmology, rare diseases, and specialty diagnostics. Their commitment to the Greater Bay Area enhances COSCIENS' reach, providing synergy between advanced healthcare solutions and localized distribution capabilities.
Navigating the Regulatory Landscape
Mr. Zheng Guo Shang, General Manager of Wuzhou, highlighted the company’s focus on regulatory and commercial interaction with healthcare systems, ensuring swift patient access to Macrilen®. This approach reflects Wuzhou’s dedication to enhancing healthcare accessibility across underserved markets.
About COSCIENS and Macrilen®
COSCIENS Biopharma is recognized for its innovative portfolio in life sciences, dedicating resources to developing natural, plant-based ingredients alongside pharmaceutical products. Macrilen® (macimorelin) stands out as their flagship pharmaceutical offering, gaining FDA and EMA approval as the first oral test for diagnosing AGHD, which is essential for health practitioners in understanding patient needs.
Looking Ahead: Strategic Focus
The agreement between COSCIENS and Wuzhou is about more than just the distribution of a product; it symbolizes a commitment to meeting modern healthcare challenges. By combining unique regulatory insights with proven market strategies, both companies aim to reshape how AGHD is diagnosed and treated, ultimately improving quality of life for patients.
Frequently Asked Questions
What is the purpose of the distribution agreement?
The agreement allows Wuzhou Drug International to manage the registration, importation, and commercialization of Macrilen® across specified regions, thus expanding its market presence.
What is Macrilen® used for?
Macrilen® (macimorelin) is an oral diagnostic test intended for the diagnosis of Adult Growth Hormone Deficiency (AGHD), providing a crucial tool for healthcare providers.
How long is the initial term of the agreement?
The initial term of the distribution agreement is set for ten years, ensuring a long-term commitment between COSCIENS and Wuzhou.
What markets will COSCIENS expand into?
COSCIENS will expand its presence into Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan through this agreement.
Who can be contacted for more information?
For inquiries, individuals can reach out to Peter H. Puccetti, the Interim CEO, or Giuliano La Fratta, the Chief Financial Officer, through their respective email addresses.
